Silymarin Inhibits In Vitro T-Cell Proliferation and Cytokine Production in Hepatitis C Virus Infection

This publication has 22 references indexed in Scilit:

• Silymarin Ascending Multiple Oral Dosing Phase I Study in Noncirrhotic Patients With Chronic Hepatitis C
  The Journal of Clinical Pharmacology, 2010
• The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity
  Drug Metabolism and Disposition, 2008
• Gram-Scale Purification of Flavonolignan Diastereoisomers from Silybum marianum (Milk Thistle) Extract in Support of Preclinical in vivo Studies for Prostate Cancer Chemoprevention
  Planta Medica, 2007
• Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application
  Journal of Pharmaceutical and Biomedical Analysis, 2007
• Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-κB Signaling, and HCV Infection by Standardized Silymarin
  Gastroenterology, 2007
• Immunopathogenesis in hepatitis C virus cirrhosis
  Clinical Science, 2007
• Silibinin polarizes Th1/Th2 immune responses through the inhibition of immunostimulatory function of dendritic cells
  Journal of Cellular Physiology, 2006
• Hepatitis C Virus–Specific Immune Responses and Quasi‐Species Variability at Baseline Are Associated with Nonresponse to Antiviral Therapy during Advanced Hepatitis C
  The Journal of Infectious Diseases, 2006
• Silibinin protects mice from T cell-dependent liver injury☆
  Journal of Hepatology, 2003
• Projecting future complications of chronic hepatitis C in the United States
  Liver Transplantation, 2003